Drug intelligence / Profile preview

VIS-954

Development stage: Phase 1
Lead developer: Taiho Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

VIS-954 is a monoclonal antibody under development by Visterra for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and transplant rejection. The drug acts as an antagonist of C5a anaphylatoxin chemotactic receptor 1 (C5AR1), a key component in the complement pathway involved in inflammatory and immune responses. VIS-954 is based on Visterra's Hierotope platform technology and is administered subcutaneously. As of 2024, it is in Phase 1 clinical trials for ANCA-associated vasculitis.

Targets

C5AR1 (Complement C5a receptor 1)

Beyond the preview

Go deeper on VIS-954.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIS-954.

Explore the full profile